echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > O medicine and chemotherapy and then "group" stomach cancer esophageal cancer patients will usher in a new treatment!

    O medicine and chemotherapy and then "group" stomach cancer esophageal cancer patients will usher in a new treatment!

    • Last Update: 2020-09-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Recently, "O-drug" Navuliyu monoanti (commodity name: Odivo) combined chemotherapy in the first-line treatment of tumor expression PD-L1 and comprehensive score (CPS) of 5 metastatic stomach cancer, gastroesophageal connection (GEJ) cancer or esophageal adenocarcinoma Phase III clinical trials.
    the trial data will be presented at a later medical conference.
    is the fifth most common cancer in the world and the third leading cause of death.
    , stomach cancer is the second-largest cancer after lung cancer, accounting for about half of all gastric cancer cases and deaths worldwide.
    so far, gastric cancer immunotherapy drugs have O and K drugs.
    In March this year, O-drug was officially approved by the China Drug Administration for the treatment of patients with advanced or relapsed stomach or gastroesophageal adenocarcinoma who had received two or more systemic treatment options in the past, and was the first immunotherapy approved in China for advanced stomach cancer.
    , However, Navuliyu monoantigen has not yet been approved in the country esophageal cancer adaptation.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.